Metastatic BRAF V600E-Mutated Thyroid Carcinoma: Molecular/Genetic Profiling Brings a New Therapeutic Option
We describe a case of a 46-year-old woman diagnosed with localized PTC 20 years ago, having already undergone several treatments with iodine-131 and then treatment with lenvatinib for metastatic disease, to which she developed intolerance. In 2020, in addition to pleural, thoracic, and abdominal lym...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2022-11-01
|
| Series: | Case Reports in Oncology |
| Subjects: | |
| Online Access: | https://www.karger.com/Article/FullText/526533 |
| _version_ | 1811300926065999872 |
|---|---|
| author | Joana S. Reis Inês Costa Mariana Costa Ana Carmo Valente Marta Baptista Freitas Catarina Lopes Almeida Marina Gonçalves Carina Teixeira Maria Ribeiro Cláudia Caeiro Catarina Fernandes Miguel Barbosa |
| author_facet | Joana S. Reis Inês Costa Mariana Costa Ana Carmo Valente Marta Baptista Freitas Catarina Lopes Almeida Marina Gonçalves Carina Teixeira Maria Ribeiro Cláudia Caeiro Catarina Fernandes Miguel Barbosa |
| author_sort | Joana S. Reis |
| collection | DOAJ |
| description | We describe a case of a 46-year-old woman diagnosed with localized PTC 20 years ago, having already undergone several treatments with iodine-131 and then treatment with lenvatinib for metastatic disease, to which she developed intolerance. In 2020, in addition to pleural, thoracic, and abdominal lymph node metastasis, progression with symptomatic vertebral bone metastasis was detected, which led to the equation of new therapeutic options. In this context, a genetic/molecular test was carried out, which identified the BRAF V600E mutation and enabled the start of treatment with dabrafenib/trametinib since June 2020. This treatment allowed functional gain, symptomatic relief, and stabilization of the disease. It demonstrates how, in rare tumors, the personalized medicine approach can bring new treatment possibilities. |
| first_indexed | 2024-04-13T06:58:43Z |
| format | Article |
| id | doaj.art-393a92b12db6443b80ac3da91f1cee76 |
| institution | Directory Open Access Journal |
| issn | 1662-6575 |
| language | English |
| last_indexed | 2024-04-13T06:58:43Z |
| publishDate | 2022-11-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Oncology |
| spelling | doaj.art-393a92b12db6443b80ac3da91f1cee762022-12-22T02:57:10ZengKarger PublishersCase Reports in Oncology1662-65752022-11-0115396096610.1159/000526533526533Metastatic BRAF V600E-Mutated Thyroid Carcinoma: Molecular/Genetic Profiling Brings a New Therapeutic OptionJoana S. ReisInês CostaMariana Costahttps://orcid.org/0000-0002-6235-1792Ana Carmo ValenteMarta Baptista Freitashttps://orcid.org/0000-0003-0383-1419Catarina Lopes Almeidahttps://orcid.org/0000-0001-9857-8692Marina GonçalvesCarina TeixeiraMaria RibeiroCláudia CaeiroCatarina FernandesMiguel BarbosaWe describe a case of a 46-year-old woman diagnosed with localized PTC 20 years ago, having already undergone several treatments with iodine-131 and then treatment with lenvatinib for metastatic disease, to which she developed intolerance. In 2020, in addition to pleural, thoracic, and abdominal lymph node metastasis, progression with symptomatic vertebral bone metastasis was detected, which led to the equation of new therapeutic options. In this context, a genetic/molecular test was carried out, which identified the BRAF V600E mutation and enabled the start of treatment with dabrafenib/trametinib since June 2020. This treatment allowed functional gain, symptomatic relief, and stabilization of the disease. It demonstrates how, in rare tumors, the personalized medicine approach can bring new treatment possibilities.https://www.karger.com/Article/FullText/526533precision oncologybraf mutationmetastatic thyroid cancerbraf inhibitorslenvatinib intolerance |
| spellingShingle | Joana S. Reis Inês Costa Mariana Costa Ana Carmo Valente Marta Baptista Freitas Catarina Lopes Almeida Marina Gonçalves Carina Teixeira Maria Ribeiro Cláudia Caeiro Catarina Fernandes Miguel Barbosa Metastatic BRAF V600E-Mutated Thyroid Carcinoma: Molecular/Genetic Profiling Brings a New Therapeutic Option Case Reports in Oncology precision oncology braf mutation metastatic thyroid cancer braf inhibitors lenvatinib intolerance |
| title | Metastatic BRAF V600E-Mutated Thyroid Carcinoma: Molecular/Genetic Profiling Brings a New Therapeutic Option |
| title_full | Metastatic BRAF V600E-Mutated Thyroid Carcinoma: Molecular/Genetic Profiling Brings a New Therapeutic Option |
| title_fullStr | Metastatic BRAF V600E-Mutated Thyroid Carcinoma: Molecular/Genetic Profiling Brings a New Therapeutic Option |
| title_full_unstemmed | Metastatic BRAF V600E-Mutated Thyroid Carcinoma: Molecular/Genetic Profiling Brings a New Therapeutic Option |
| title_short | Metastatic BRAF V600E-Mutated Thyroid Carcinoma: Molecular/Genetic Profiling Brings a New Therapeutic Option |
| title_sort | metastatic braf v600e mutated thyroid carcinoma molecular genetic profiling brings a new therapeutic option |
| topic | precision oncology braf mutation metastatic thyroid cancer braf inhibitors lenvatinib intolerance |
| url | https://www.karger.com/Article/FullText/526533 |
| work_keys_str_mv | AT joanasreis metastaticbrafv600emutatedthyroidcarcinomamoleculargeneticprofilingbringsanewtherapeuticoption AT inescosta metastaticbrafv600emutatedthyroidcarcinomamoleculargeneticprofilingbringsanewtherapeuticoption AT marianacosta metastaticbrafv600emutatedthyroidcarcinomamoleculargeneticprofilingbringsanewtherapeuticoption AT anacarmovalente metastaticbrafv600emutatedthyroidcarcinomamoleculargeneticprofilingbringsanewtherapeuticoption AT martabaptistafreitas metastaticbrafv600emutatedthyroidcarcinomamoleculargeneticprofilingbringsanewtherapeuticoption AT catarinalopesalmeida metastaticbrafv600emutatedthyroidcarcinomamoleculargeneticprofilingbringsanewtherapeuticoption AT marinagoncalves metastaticbrafv600emutatedthyroidcarcinomamoleculargeneticprofilingbringsanewtherapeuticoption AT carinateixeira metastaticbrafv600emutatedthyroidcarcinomamoleculargeneticprofilingbringsanewtherapeuticoption AT mariaribeiro metastaticbrafv600emutatedthyroidcarcinomamoleculargeneticprofilingbringsanewtherapeuticoption AT claudiacaeiro metastaticbrafv600emutatedthyroidcarcinomamoleculargeneticprofilingbringsanewtherapeuticoption AT catarinafernandes metastaticbrafv600emutatedthyroidcarcinomamoleculargeneticprofilingbringsanewtherapeuticoption AT miguelbarbosa metastaticbrafv600emutatedthyroidcarcinomamoleculargeneticprofilingbringsanewtherapeuticoption |